GlobalData is the parent company of Clinical Trials Arena. "Ocugen sets sights on Phase III after GA gene therapy win" was ...

The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...

-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...

Top Employers Institute recognizes Boehringer Ingelheim as Global Top Employer 2026: Ingelheim, Germany Friday, January 16, 2026, 12:00 Hrs [IST] For the sixth year in a row, the ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic ...

A strategic partnership with CommonSpirit Health aims to increase adherence to evidence-based guidelines (EBGs), improving screening and diagnosis of cardio-kidney-metabolic (CKM) diseases -- The ...

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...

Boehringer Ingelheim enters clinical collaboration with Jazz Pharma to advance HER2-targeted therapy in breast cancer: Ingelheim, Germany Wednesday, January 14, 2026, 16:00 Hrs [I ...

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany- 12 January, 2026 - Boehringer Ingelheim today announced a strategic ...

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...